Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension.

Trial Profile

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Netarsudil (Primary) ; Timolol
  • Indications Glaucoma; Ocular hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms Rocket 4
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2017 Status changed from active, no longer recruiting to completed, according to an Aerie Pharmaceuticals media release.
    • 12 Apr 2017 According to an Aerie Pharmaceuticals media release, this study will provide six-month safety data adequate for regulatory filing in Europe and is not required for U.S. FDA approval. The European regulatory filing for Rhopressa is currently expected to take place in the second half of 2018.
    • 12 Apr 2017 Six-month topline safety and efficacy results published in an Aerie Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top